Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $767 from $756 and keeps an Overweight rating on the shares following a Q3 beat on the top and bottom line. While noting that commentary on 2026 expenses suggests upward pressure relative to consensus, the firm also says it is “encouraged” that the company continues to work towards a path to resolution of Eylea HD fill and finish issues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
- Early notable gainers among liquid option names on October 28th
- Morning Movers: UPS and PayPal jump following quarterly reports
- Regeneron reports Q3 non-GAAP EPS $11.83, consensus $9.64
- Regeneron still sees 2025 CapEx $880M-$950M